Athira Pharma, Inc. — Director's Dealing 2022

Apr 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-04-12

Reporting Person: MILESON GLENNA (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-11	Common Stock	M	3000	$10.64	Acquired	100060	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-11	Stock Option (right to buy)	$10.64	M	3000	Disposed	2032-01-17	Common Stock (3000)	Direct

Footnotes

F1: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter.